| abstract |
IT REFERS TO 4,5-DIARYLIMIDAZOLE-2-SUBSTITUTED, WHERE N IS REPLACED BY TRIALKYLSILIL, THE SUBSTITUTE IN POSITION 2 IS ARYLALKYL, ARYLSULFONYL, THIOARYL, ARYLSELENIUM, AMONG OTHERS; A COMPOUND OF FORMULA (I), WHERE R1 IS 4-PYRIDYL, PYRIMIDINYL, QUINAZOLIN-4-ILO, AMONG OTHERS; R2 IS PHENYL, NAFT-1-ILO � NAFT-2-ILO; R3 IS H, HETEROCYCLE, C1-C10 HETERO CYCLYLALKYL, AMONG OTHERS; R4 IS ZERO-4- (MONO-) OR (DI-CYCLOALKYL C3-C7) ALKYL OPTIONALLY SUBSTITUTED, NR7R8, NHNHR9, X-ARYL C5-C10; R7, R8 AND R9 ARE C1-C4 ALKYL; C2-C4 ALKENYL; X IS S, SO2, Se, Te OR C1-C4 ALKYL. WHEN R3 IS NOT TRIALKYL C1-C4, SILYLALCOXY C1-C10; R4 IS NOT ARYL, HETEROARYL, PIPERIDIN-4-ILO. ALSO REFERS TO A COMPOUND OF FORMULA I`, WHERE R3 'IS TRIALKYL C1-C4, SILILALCOXI C1-C10, ALKYL C1-C4. A PREFERRED COMPOUND IS 4- (4-FLUOROPHENYL) -5- (4-PYRIDYL) -1- (2-TRIMETHYLSILYLETOXIMETHYL) IMIDAZOLE, AMONG OTHERS. IT ALSO REFERS TO A PROCEDURE FOR PREPARATION. COMPOUND I INHIBITS THE SOLUBLE TUMOR NECROSIS FACTOR, REDUCES INFLAMMATION AND MAY BE USED AS AN IMMUNOSUPPRESSOR OR ANTI-INFLAMMATORY AGENT |